Rapid Development of Graves' Ophthalmopathy After Treatment With Ipilimumab and Recurrence With Pembrolizumab in a Patient With Previously Treated Graves' Disease

J Oncol Pract. 2018 Dec;14(12):747-749. doi: 10.1200/JOP.18.00442.
No abstract available

Publication types

  • Case Reports

MeSH terms

  • Aged, 80 and over
  • Antibodies, Monoclonal, Humanized / administration & dosage
  • Antibodies, Monoclonal, Humanized / adverse effects
  • Graves Disease / complications
  • Graves Disease / drug therapy*
  • Graves Disease / pathology
  • Graves Ophthalmopathy / chemically induced
  • Graves Ophthalmopathy / drug therapy*
  • Graves Ophthalmopathy / pathology
  • Humans
  • Ipilimumab / administration & dosage*
  • Ipilimumab / adverse effects
  • Lung Neoplasms / chemically induced
  • Lung Neoplasms / pathology*
  • Lung Neoplasms / secondary
  • Male
  • Recurrence

Substances

  • Antibodies, Monoclonal, Humanized
  • Ipilimumab
  • pembrolizumab